Is GMED a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Globus Medical (GMED) rests on NuVasive integration and operating leverage: The merger's promised cost synergies are now showing up in reported numbers rather than slides, with adjusted EBITDA margin near 35% and non-GAAP EPS growing several times faster than revenue. The bear case rests on the largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Analysts covering it publish targets from $75.00 to $110.00 against a $70.50 share price on November 16, 2026, so even the professionals disagree by 37% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

GMED key stats

At $70.50 on November 16, 2026, Globus Medical (GMED) has a market cap of $9.4B and a P/E of 17.4 on trailing earnings (13.2 on forward earnings).

Market cap
$9.4B
P/E (trailing)
17.4
P/E (forward)
13.2
EPS (trailing 12 months)
$4.06
Price to book
2.0
Beta
0.95

Market cap, P/E and yield are measured at the $70.50 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Globus Medical (GMED)?

The last two weeks for Globus Medical, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • GMED closed at $70.50 on November 16, 2026, down 7.7% over the past five trading days (from $76.37).
  • On November 5, 2026, Globus Medical filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, Globus Medical filed an 8-K with the SEC reporting quarterly results and other events (Item 2.02, Item 8.01). Read the 8-K on sec.gov
  • On November 9, 2026, Truist Securities lowered its target to $90.00 from $100.00 (Buy).
  • On November 6, 2026, Canaccord Genuity lowered its target to $105.00 from $115.00 (Buy).
  • On November 6, 2026, Wells Fargo raised its target to $100.00 from $99.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Globus Medical designs and sells musculoskeletal implants and the enabling technology used to place them. The core business is spine: pedicle screws, interbody cages, cervical plates, expandable implants and the disposable instruments that go with them, sold to hospitals and surgery centers largely through a direct sales force. Sitting on top of that is the enabling-technology line, principally the ExcelsiusGPS robotic navigation platform, the Excelsius3D imaging system and the Excelsius Flex robot aimed at knee replacement. The robots themselves are a modest share of revenue; their commercial purpose is to place capital in a hospital and pull recurring implant volume through it for years afterward. The September 2023 all-stock merger with NuVasive roughly doubled the company's size and made it the second largest spine business in the world behind Medtronic, and the April 2025 acquisition of Nevro added spinal cord stimulation for chronic pain, extending Globus beyond surgical implants into neuromodulation. The investment picture in October 2026 is mostly about integration paying off. Q2 2026 revenue was about $789.6 million, up roughly 6% as reported and around 9% excluding Nevro, with US Spine up about 7% (a fifth straight quarter the company describes as above-market) and international spine up about 14%. The margin story is the sharper one: adjusted EBITDA margin reached roughly 35.4%, an expansion of about 740 basis points year over year, and non-GAAP EPS of about $1.34 grew roughly 56%. Management reaffirmed full-year revenue guidance of about $3.18 billion to $3.22 billion and raised non-GAAP EPS guidance to roughly $4.95 to $5.05 from $4.70 to $4.80. Against that, Nevro sales fell about 14% year over year and management does not expect trial volumes to recover until late in Q4 2026, and a July 2024 FDA warning letter concerning complaint handling and adverse-event reporting for ExcelsiusGPS remains part of the backdrop. The Q2 print extended a run of four straight quarters of non-GAAP EPS above consensus (the $1.34 compared with an estimate of about $1.10). The stock has not followed the earnings: as of October 16, 2026 GMED closed near $77.94, down about 11% year to date though still up about 33% over the past year, for a market value of roughly $10.5 billion. Globus reports Q3 2026 results on November 5, 2026, with consensus looking for non-GAAP EPS of about $1.20 on roughly $792 million of revenue, which would be revenue growth of only a few percent while Nevro remains a drag.

The bull case: what would have to be true for $110.00

The most optimistic published target on GMED is $110.00, +56.0% from the $70.50 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. NuVasive integration and operating leverage.

The merger's promised cost synergies are now showing up in reported numbers rather than slides, with adjusted EBITDA margin near 35% and non-GAAP EPS growing several times faster than revenue. Combining two direct sales forces, consolidating manufacturing and rationalizing overlapping implant lines is the mechanism. How much further this runs is the main swing factor in the next few years of earnings, because the revenue growth rate alone does not explain the EPS growth rate.

2. Robotics as an implant channel.

ExcelsiusGPS placements matter less for the capital revenue they generate than for the implant pull-through that follows, since a hospital that installs a Globus robot tends to standardize on Globus screws and cages. Excelsius3D imaging and the Excelsius Flex knee robot extend the same logic into imaging and orthopedics, where Stryker's Mako already set the pattern. The installed base is effectively a switching-cost asset, and its growth rate is a better leading indicator of future implant share than any single quarter's revenue.

3. Competitive recruiting and international expansion.

Globus attributes much of its above-market US spine growth to recruiting surgeons and distributors away from rivals, which is a repeatable but not infinite lever. International spine grew about 14% in Q2 2026 with double-digit gains across EMEA, APAC and Latin America, off a smaller base than the US and with more room left. The NuVasive combination gave the company a broader international footprint than either had alone.

4. Neuromodulation via Nevro.

The Nevro acquisition brought high-frequency spinal cord stimulation for chronic pain, a market adjacent to spine surgery and served by the same physicians. It is currently a drag: sales fell about 14% year over year in Q2 2026, and management points to late Q4 2026 before trial volumes recover. Whether Globus's larger sales channel can stabilize a franchise that was losing share before the deal is an open question, and the answer determines whether this becomes a growth line or a written-down one.

5. Q3 2026 results on November 5.

Consensus for the third quarter is non-GAAP EPS of about $1.20 on revenue of about $792 million, against $1.18 a year earlier, so expectations assume margins hold while revenue growth slows. Globus has beaten the EPS estimate in each of the last four quarters, by margins ranging from about $0.13 to $0.40. The report will also update whether Nevro trial volumes are on the path management laid out for a late Q4 2026 recovery.

The bear case: what would have to be true for $75.00

The most pessimistic published target is $75.00, +6.4% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Globus Medical is worth if the risks below bite instead of the drivers above.

The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Competition is heavy on both flanks, with Medtronic and its Mazor platform on one side and fast-growing challengers such as Alphatec taking surgeon share on the other, and the surgeon-recruiting lever that drives current outperformance can run in reverse. Regulatory exposure is concrete rather than theoretical: the July 2024 FDA warning letter concerning ExcelsiusGPS complaint handling and medical device reporting is the kind of matter that can escalate to consent decrees or shipment holds if not resolved. Nevro is shrinking, and management's own recovery timeline extends into late 2026, so an impairment is possible if trial volumes stay weak. Plaintiff firms have publicly announced investigations following the 2025 revenue miss and the FDA letter, and product-liability activity around spinal cord stimulators adds separate legal cost that is hard to size in advance.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding GMED already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on GMED

14 analysts cover GMED, with an average target of $93.43 (+32.5% against $70.50) and a split of 10 buy, 5 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the GMED forecast and price target page.

How is GMED valued?

Market cap, P/E and dividend yield at today's price are in the GMED key stats above. The business figures below come from Globus Medical's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$3.14 billion
  • Q2 2026 revenue: ~$789.6 million, up ~6% year over year (~9% excluding Nevro)
  • Margins (TTM): ~69% gross, ~25% operating, ~17% net
  • FY2026 guidance: Revenue ~$3.18 to ~$3.22 billion; non-GAAP EPS raised to ~$4.95 to ~$5.05

As of October 2026: At roughly $77.94 a share against 2026 consensus non-GAAP EPS of about $5.00 and 2027 consensus near $5.40, Globus trades around 14 to 16 times forward earnings and about 3.3 times trailing revenue, a discount to large-cap medtech peers. The shares have fallen about 11% in 2026 despite four consecutive earnings beats, which suggests the market is discounting slowing revenue growth and the Nevro drag more than it is rewarding margin expansion. The balance sheet is light, with about $595 million of cash against roughly $112 million of debt.

How do you decide if GMED is a buy?

Whether GMED is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold GMED indirectly through an index or sector ETF before adding more.

What would change your mind on GMED

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: NuVasive integration and operating leverage stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: the largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the GMED stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about GMED against your real portfolio and see your actual exposure before deciding.

Your questions about Globus Medical

Ask Walnut's AI anything about GMED and see how it fits what you own.

FAQ

Is GMED a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on NuVasive integration and operating leverage, with revenue (ttm) at ~$3.14 billion. The bear case rests on the largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Analysts covering it are spread from $75.00 to $110.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell GMED?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $75.00, +6.4% from the $70.50 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for GMED?

+

NuVasive integration and operating leverage. The merger's promised cost synergies are now showing up in reported numbers rather than slides, with adjusted EBITDA margin near 35% and non-GAAP EPS growing several times faster than revenue. The most optimistic analyst target on GMED is $110.00, +56.0% from the $70.50 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for GMED?

+

The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Competition is heavy on both flanks, with Medtronic and its Mazor platform on one side and fast-growing challengers such as Alphatec taking surgeon share on the other, and the surgeon-recruiting lever that drives current outperformance can run in reverse. Regulatory exposure is concrete rather than theoretical: the July 2024 FDA warning letter concerning ExcelsiusGPS complaint handling and medical device reporting is the kind of matter that can escalate to consent decrees or shipment holds if not resolved. Nevro is shrinking, and management's own recovery timeline extends into late 2026, so an impairment is possible if trial volumes stay weak. Plaintiff firms have publicly announced investigations following the 2025 revenue miss and the FDA letter, and product-liability activity around spinal cord stimulators adds separate legal cost that is hard to size in advance. The most pessimistic published target is $75.00, +6.4% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Globus Medical do?

+

The second largest spine implant company after the NuVasive merger, pairing implants with the ExcelsiusGPS surgical robot.

What would have to change for GMED to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (NuVasive integration and operating leverage) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Globus Medical actually sell?

+

Mostly spinal implants and the instruments used to place them: pedicle screws, interbody cages, cervical plates and expandable devices, sold to hospitals and surgery centers through a largely direct sales force. On top of that sits enabling technology, principally the ExcelsiusGPS robotic navigation system, Excelsius3D imaging and the Excelsius Flex knee robot. Since April 2025 it also sells Nevro spinal cord stimulators for chronic pain. Implants and disposables, not robots, generate the large majority of revenue.

Is Globus Medical a robotics company or an implant company?

+

An implant company that uses robotics commercially. Robot capital sales are a small slice of revenue; the strategic value of an ExcelsiusGPS placement is that the hospital then standardizes on Globus implants for the procedures done on it. That makes the installed base a distribution asset with switching costs attached, which is why the company reports enabling-technology placements as a leading indicator rather than as a profit center in its own right.

How did the NuVasive merger change the company?

+

The all-stock merger closed in September 2023 and roughly doubled Globus's revenue, making it the second largest spine company in the world behind Medtronic and giving it a much larger international footprint. The financial payoff has come more through cost synergies than through revenue: Q2 2026 adjusted EBITDA margin of about 35.4% was up roughly 740 basis points year over year while revenue grew about 6%. Merger amortization is also why GAAP and non-GAAP earnings differ so widely.

Walnut is informational, not investment advice, and gives no verdict on GMED. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks